Amphastar Pharmaceuticals, Inc. Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Amphastar Pharmaceuticals, Inc. (AMPH) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $1.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-02-26
- Amphastar Pharmaceuticals, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $1.90M, a 28.69% decline from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $2.66M, a 28.21% increase from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2023 was $2.07M, a 26.23% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2022 was $1.64M, a 6.33% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month |
|---|---|
| 2025-12-31 | $1.90M 10-K · filed 2026-02-26 |
| 2024-12-31 | $2.66M 10-K · filed 2026-02-26 |
| 2023-12-31 | $2.07M 10-K · filed 2026-02-26 |
| 2022-12-31 | $1.64M 10-K · filed 2025-03-03 |
| 2021-12-31 | $1.75M 10-K · filed 2024-02-29 |
| 2020-12-31 | $1.81M 10-K · filed 2023-03-01 |
| 2019-12-31 | $1.38M 10-K · filed 2022-03-11 |
| 2018-12-31 | $1.30M 10-K · filed 2021-03-15 |
| 2017-12-31 | $1.30M 10-K · filed 2020-03-16 |
| 2016-12-31 | $903.00K 10-K · filed 2019-03-15 |
| 2015-12-31 | $812.00K 10-K · filed 2018-03-14 |
| 2014-12-31 | $655.00K 10-K · filed 2017-03-15 |
| 2013-12-31 | $766.00K 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |